Skip to main content
$193.09 -$2.62 (-1.3%)

04:00 PM EDT on 05/19/22

Biogen Inc (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Current Price $193.09 Mkt Cap $28.3B
Open $195.32 P/E Ratio 19.70
Prev. Close $193.09 Div. (Yield) $0.00 (0.0%)
Daily Range $191.46 - $195.55 Volume 7
52-Wk Range $187.16 - $468.55 Avg. Daily Vol. 1,072,036

Caps

How do you think NASDAQ:BIIB will perform against the market?

Add Stock to CAPS Watchlist

All Players

958 Outperform
77 Underperform
 

All-Star Players

215 Outperform
14 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BIIB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

BayouBink (20.44)
Submitted January 12, 2022

Biogen is beat down because of all of the controversy surrounding its Alzheimer’s drug. It is now actually worth $50/share less since Aduhelm Was approved. It is at a 5 year low. The company would probably actually have a higher market cap if Aduhelm… More

LeakyWallet (< 20)
Submitted July 23, 2021

Seems like the poor testing process control or outright fraud might be systemic within the company - kind of like the pharma version of Boeing MAX.

Recent Community Commentary

Read the most recent pitches from players about BIIB.

Recs

1
Member Avatar BayouBink (20.44) Submitted: 1/12/2022 6:09:06 AM : Outperform Start Price: $220.30 NASDAQ:BIIB Score: +5.07

Biogen is beat down because of all of the controversy surrounding its Alzheimer’s drug. It is now actually worth $50/share less since Aduhelm Was approved. It is at a 5 year low. The company would probably actually have a higher market cap if Aduhelm had bee rejected, which makes zero sense.

Recs

0
Member Avatar TMFSecurity (93.98) Submitted: 11/16/2021 9:09:05 AM : Underperform Start Price: $268.27 NASDAQ:BIIB Score: +11.38

10000000146

Recs

2
Member Avatar TMFAdriaCimino (< 20) Submitted: 10/12/2021 5:54:34 AM : Outperform Start Price: $285.48 NASDAQ:BIIB Score: -21.74

I think Biogen is at a turning point. The company's blockbuster MS revenue is declining. But it has several potential products in phase 3 studies in various treatment areas. I expect Biogen to return to growing revenue and profit as new products come to market.

Leaderboard

Find the members with the highest scoring picks in BIIB.

Score Leader

optioncoach

optioncoach (93.96) Score: +637.71

The Score Leader is the player with the highest score across all their picks in BIIB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
fwhittlesey < 20 4/12/2007 Outperform 3Y $43.64 +342.46% +186.39% +156.07 1 Comment
RafaelCanadaRed 85.02 5/7/2013 Underperform 5Y $214.81 -10.11% +140.17% +150.28 0 Comment
tradersinsights 47.20 4/10/2007 Outperform 1Y $44.42 +334.69% +184.87% +149.82 1 Comment
resistanceps3 < 20 4/2/2013 Underperform 5Y $196.30 -1.64% +147.95% +149.58 0 Comment
52weekhighs 65.74 5/14/2012 Underperform 5Y $135.87 +42.11% +189.91% +147.80 0 Comment
wsjpearson 24.48 6/13/2013 Underperform 5Y $209.45 -7.81% +139.09% +146.90 0 Comment
ambina < 20 3/12/2007 Outperform NS $43.95 +339.34% +193.43% +145.91 0 Comment
nickysone 69.29 4/9/2007 Outperform 3Y $44.86 +330.43% +184.60% +145.83 1 Comment
mgroeber < 20 4/9/2007 Outperform NS $44.86 +330.43% +184.60% +145.83 0 Comment
anewday101 90.62 3/5/2007 Outperform 1Y $43.36 +345.32% +199.65% +145.67 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BIIB.